Business
Novo Nordisk Shares Plunge 20% After Disappointing CagriSema Trial Results
Novo Nordisk experienced its sharpest one-day decline in history on Friday as shares of the Danish pharmaceutical giant plummeted 20% following underwhelming trial results for its new obesity drug, CagriSema. The drop wiped out €90 billion in market valuation, significantly impacting the year-to-date performance of Europe’s largest company, which is now down 16% in 2024.
CagriSema Misses Expectations
The phase 3 trial for CagriSema revealed a weight loss of 22.7% over 68 weeks, below the projected 25% benchmark. The figure fell further to 20.4% among patients who did not strictly adhere to the treatment regimen. The results raised concerns about Novo Nordisk’s competitiveness in the rapidly growing obesity and diabetes drug market.
Eli Lilly, Novo Nordisk’s primary U.S.-based rival, reported a 24% weight loss in September with its latest drug, retatrutide. Eli Lilly’s stock surged 10% before closing 1.35% higher on Friday and has gained 32% this year, a stark contrast to Novo Nordisk’s performance.
Adding to the disappointment, only 57% of CagriSema trial participants reached the highest dose, compared to 83% for cagrilintide and 70% for semaglutide in previous studies. Concerns about the drug’s side effects and market positioning have tempered investor expectations.
“Based on insights from the REDEFINE 1 trial, we will explore additional weight loss potential for CagriSema,” said Martin Holst Lange, Novo Nordisk’s executive vice president for Development. Results from a second phase 3 trial, REDEFINE 2, are expected in the first half of 2025.
Heightened Competition in the Weight-Loss Market
The global market for weight-loss and diabetes drugs, including GLP-1 treatments, is projected to grow to between $150 billion and $200 billion by 2030. Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic accounted for 61% of the company’s sales in the first nine months of 2024.
Eli Lilly has emerged as a formidable competitor with its weight-loss drugs Zepbound and Mounjaro. The U.S.-based company, valued at $691 billion (€662 billion), has positioned itself as a market leader, with analysts expecting the two firms to evenly split the weight-loss market by the end of 2024.
Future Challenges for Novo Nordisk
Novo Nordisk faces mounting pressure to expedite next-generation drug development as the patent for Wegovy is set to expire in the early 2030s. The disappointing results for CagriSema have raised doubts about the company’s ability to sustain its dominance in the sector.
The U.S. remains Novo Nordisk’s largest market, accounting for 35% of its diabetes drug sales as of August 2024. While the company’s valuation peaked in June, Friday’s market reaction underscores the challenges it faces in retaining its competitive edge in a rapidly evolving industry.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
